 1  Diurnal Group plc _ Annual Report 2017
Highlights
Operational
 + Primary endpoint successfully met in European Phase III Infacort
®
 registration 
trial in paediatric AI
 + Infacort
®
 paediatric use marketing authorisation (PUMA) submitted to the 
European Medicines Agency (EMA)
 + First patient dosed in food matrix compatibility study intended to form part 
of US Phase III registration package for Infacort
®
; expanded global patent 
estate with first US patent granted for Infacort
®
 + Completed first phase of establishing the Company’s European commercial 
infrastructure and implemented the commercial supply chain for Infacort
®
 + Significant progress in the European Phase III trial of Chronocort
®
 in CAH, 
with over 75% of patients enrolled
Financial
 + Operating loss of £12.1m (2016: £7.0m) reflecting increased investment 
to support the Group’s anticipated development
 + Cash and cash equivalents and held to maturity financial assets at 30 June 2017 
of £19.9m (2016: £30.1m)
 + Net cash used in operating activities was £10.5m (2016: £5.1m), in line with 
the Board’s expectations
Post-period highlights
 + In line with regulatory evaluation, submitted responses to “Day 120 questions” 
received from the EMA following review of the Infacort
® 
PUMA package
 + Submitted a proposed Phase III pivotal US registration study design and 
supporting data package for Chronocort
®
 to the US Food and Drug 
Administration (FDA)
 + Further expanded global patent estate with first US patent granted for Chronocort
®
£19.9m
Research and development 
expenditure (£m) 
£8.3m
2015
2017
2016
2.2
8.3
3.9
2015
2017
2016
6.1
19.9
30.1
Cash and cash equivalents and held 
to maturity financial assets (£m) 
